Mutation-in-Brief

A Novel V185DfsX4 Mutation of the AAAS Gene in a 2-year-old Boy with Triple A Syndrome

Tony Huynh¹, Ivan McGown², Ohn Nyunt¹, David Cowley², Mark Harris¹,

Andrew M Cotterill¹, and Gary M Leong¹

¹Department of Paediatric Endocrinology and Diabetes, Mater Children's Hospital, South Brisbane, Queensland, Australia

²Department of Clinical Chemistry, Mater Health Services, South Brisbane, Queensland, Australia

Introduction

Triple A Syndrome is an autosomal recessive neurodegenerative disorder characterised by central and peripheral nervous system disturbances, autonomic dysfunction, alacrima, achalasia, and ACTH-resistant adrenal insufficiency (1). It results from mutations in the AAAS gene located on 12q13 which encodes the WD-repeat protein ALADIN (2) (ALacrima Achalasia aDrenal Insufficiency Neurologic disorder). We report a case of a 2 yr old boy with a genetically confirmed diagnosis of Triple A Syndrome resulting from a previously unreported mutation of the AAAS gene.

Patient Report

The patient presented at the age of 2 yr 2 mo with a hypoglycaemic (glucose 1.0 mmol/l) seizure and cardiovascular collapse in the context of a Respiratory Syncytial Virus (RSV) respiratory illness. He was the result of a non-consanguineous union. His development had been normal and there had been no history of neurological or gastrointestinal problems. There was, however, a consistent history of alacrima since birth. Apart from hyperpigmentation his examination was unremarkable, including normal growth and male genitalia. Initial investigations revealed combined glucocorticoid (ACTH > 1,250 ng/l, cortisol 140 nmol/l) and mineralocorticoid (Na⁺ 130 mmol/l, K⁺ 4.6 mmol/l, aldosterone < 70 pmol/l) deficiency associated with a metabolic acidosis (bicarbonate 18 mmol/l). Autoimmune adrenalitis and Adrenoleukodystrophy were excluded as causes of his primary adrenal insufficiency.

After obtaining informed consent direct sequencing of leucocyte DNA confirmed Triple A (Allgrove) Syndrome (OMIM#231550). The patient was heterozygous for a known mutation of the AAAS gene, a C>A nucleotide transversion at position 43 in exon 1 resulting in the replacement of a Glutamine with Lysine at amino acid position 15 (p.Gln15Lys) (3) and a previously undescribed mutation resulting in the deletion of two nucleotides and an insertion of a single "A" nucleotide in exon 7 (c.554_55delTCinsA) (see Fig. 1).

Discussion

The WD-repeat family of regulatory proteins are involved in multiple functions including

Received: August 18, 2008

Accepted: December 15, 2008

Correspondence: Dr. Tony Huynh, Department of Paediatric Endocrinology and Diabetes, Mater Children's Hospital, South Brisbane, Queensland, Australia

E-mail: tony.huynh@mater.org.au.



Fig. 1 Electrochromatograms showing the two mutations found in the patient. p.Q15K on exon 1 has been previously described while p.V185DfsX4 on exon 7 is a novel mutation.



Fig. 2 Schematic representation of the *AAAS* gene and the published mutations to date (1, 5) including the novel V185DfsX4 in exon 7 found in our patient.

transmembrane signalling, transcription, cell division and intracellular trafficking. The precise role of ALADIN is unknown but it is thought to be a scaffold protein in the nuclear pore complex (NPC) of cells, with mutations resulting in functional rather than structural abnormalities (2). To date there is little evidence supporting a strong genotype-phenotype correlation (1) with one report describing eight patients with considerable variation in both age of presentation and onset of characteristic features despite sharing a common p.Ser263Pro homozygous mutation (4).

In addition to the previously described pGln15Lys or G15K mutation (3), we have identified a novel mutation (c.554 55delTCinsA) of AAAS in a boy with Triple A syndrome. The mutation involves a deletion of two nucleotides and an insertion of a single "A" nucleotide in exon 7 corresponding to the DNA sequence ATAG[TC]ACCCTCCCT. Thec.554_55delTCinsA causes a frameshift starting with codon Valine 185, changing it to Aspartic Acid, and creates a premature stop codon at position 4 of the new reading frame (p.V185DfsX4) resulting in truncation of the C terminus (see Fig. 2). Although the functional implications of this novel mutation require further investigation the C terminus is important for targeting the ALADIN protein to the NPC. In-vitro studies have confirmed that there is a critical region between amino acids 478 and 499, without which the truncated ALADIN protein remains localised in the cytoplasm.

More detailed functional studies of *AAAS* gene mutations will hopefully allow a greater

understanding of the role that ALADIN plays in macromolecular exchange between the cytoplasm and nucleus.

References

- 1. Brooks BP, Kleta R, Stuart C, Tuchman M, Jeong A, Stergiopoulos SG, *et al.* Genotypic heterogeneity and clinical phenotype in triple A syndrome: a review of the NIH experience 2000–2005. Clin Genet 2005;68:215–21.
- Cronshaw JM, Matunis MJ. The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome. Proc Natl Acad Sci U S A 2003;100:5823–7.
- 3. Handschug K, Sperling S, Yoon SJ, Hennig S, Clark AJ, Huebner A. Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Hum Mol Genet 2001;10:283–90.
- Milenkovic T, Koehler K, Krumbholz M, Zivanovic S, Zdravkovic D, Huebner A. Three siblings with triple A syndrome with a novel frameshift mutation in the AAAS gene and a review of 17 independent patients with the frequent p. Ser263Pro mutation. Eur J Pediatr 2008;167:1049-55.
- Collares CV, Antunes-Rodrigues J, Moreira AC, Franca SN, Pereira LA, Soares MM, *et al.* Heterogeneity in the molecular basis of ACTH resistance syndrome. Eur J Endocrinol 2008;159:61-8.